Galderma sets price range for supersized $2.6bn IPO in Europe
Pharmaceutical Technology
MARCH 13, 2024
The dermatology-centric pharma company is likely set for one of the biggest public listings in Europe since 2022.
130 
Almirall kicks off another hunt for skin disease therapy partnerships
pharmaphorum
JULY 5, 2021
Spanish drugmaker Almirall has launched another search for early-stage research projects that it can partner in dermatology, its core area of expertise. ” Earlier iterations have focused on immuno-inflammatory skin conditions, novel targets for skin health and pharmacological validated research models in skin diseases.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Novartis probed by Swiss authorities over ‘unlawful’ patent use
pharmaphorum
SEPTEMBER 15, 2022
The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company – now confirmed to be Novartis – as part of an investigation into a “possible unlawful use of a patent to reduce competitive pressure.”
Almirall and IRB Barcelona team up to tackle skin disease
pharmaphorum
JANUARY 18, 2022
Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. It’s an amazing opportunity to put their knowledge and experience in dermatology, together with our expertise in molecular glues to accelerate drug discovery to treat skin diseases.
Takeaways From The American Academy of Dermatology’s Annual Conference
Pharma Marketing Network
APRIL 4, 2022
The American Academy of Dermatology (AAD) held its annual conference last weekend, and it was my privilege to be in attendance. As COVID-19 had put the brakes on the show for the past two years, that same sentiment was shared by most of the attendees and exhibitors this year.
First Stelara Biosimilar, Wezlana, Gets FDA Nod for Crohn’s, UC, Psoriasis but Faces Delayed Launch
XTalks
NOVEMBER 2, 2023
The biosimilar to Johnson & Johnson’s Stelara is approved for use by adults for the listed indications, as well as pediatric patients six years of age and older for the dermatologic indications (plaque psoriasis and psoriatic arthritis). billion in sales, accounting for ten percent of Johnson & Johnson’s revenue.
Top Life Science News and Trends in 2023 at Xtalks
XTalks
DECEMBER 20, 2023
Check out this article to learn about the biotech companies that went public this year. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.
Let's personalize your content